ImmunityBio enters its May 8 earnings call navigating a securities fraud lawsuit, a wave of class-action filings over alleged drug promotion violations, and 14% of its float shorted — a combination that makes the upcoming print one of the more charged setups in small-cap biotech right now.
The short side tells the dominant story here. Short interest at 14.3% of free float is not a fringe position — it is a meaningful structural bet against the stock. That level has edged up about 4% over the past month, suggesting shorts have been quietly rebuilding rather than covering into the recent rally. The ORTEX short score of 77.7 ranks in the bottom 5% of the universe for short-side pressure, a reading that has held stubbornly steady for weeks. What makes the borrow picture especially notable is how tight availability has become: with utilization near 95% and the 52-week peak at 100%, there are very few shares left in the lending pool. Anyone looking to add a new short position faces a constrained supply of borrows. Cost to borrow has eased from its March high near 17% to around 6.9% — a meaningful drop, but still elevated enough to make holding a short position expensive over time.
Options positioning offers a mild counterpoint. The put/call ratio of 0.35 is almost exactly in line with its 20-day average of 0.36, with a z-score of essentially zero. That neutral reading suggests options traders are not particularly hedged into earnings — there is no unusual scramble for downside protection visible in the derivatives market, which stands in some contrast to the elevated short interest from the stock-lending side.
The analyst community is uniformly constructive, though the picture is more concentrated than the headline "buy" consensus implies. D. Boral Capital has maintained its Buy rating and $23 target repeatedly over the past several months, most recently on May 5. BTIG initiated with a Buy in March at a $13 target, and Piper Sandler reiterated Overweight after lifting its target to $12 in early March following a strong earnings print. With the stock at $7.58, the mean target of $15.75 implies substantial upside on paper — but the wide range between the $12 Piper target and Boral's $23 reflects real disagreement on how quickly ANKTIVA can scale globally. The bull case rests on the IL-15 superagonist ANKTIVA expanding into new geographies and indications, non-dilutive financing improving balance-sheet flexibility, and upcoming catalysts in BCG-naïve NMIBC, prostate cancer, and ovarian cancer. The bear case centres on insider-linked financing arrangements, heavy reliance on affiliated capital, and the fresh legal overhang from the FDA drug promotion warning and resulting securities fraud class actions.
The insider data adds a layer of context, though it is dated to late February. At that point, multiple insiders sold shares — including Executive Director Barry Simon, Director Christobel Selecky, and founder and Chief Medical Officer Patrick Soon-Shiong — in the days immediately following a large post-earnings spike of 33%. Selling into strength after a big move is a different read from distribution at a low; the net 90-day insider figure is modestly positive in share terms due to stock awards, rather than open-market buying. The founder still controls roughly 28% of shares directly, with affiliated entities adding further concentrated insider ownership above 60% of the company.
Earnings history reinforces the volatility profile. The February 23 print produced a 33% single-day gain followed by a further 20% over five days. That same announcement period was preceded by a March event that saw the stock give back 14% in a day and 23% over the week. The range of outcomes has been extreme in both directions. The stock is up 9% on the week heading in, recovering from the losses tied to the FDA warning that triggered the securities litigation.
The May 26 class-action deadline, the FDA warning backdrop, and the earnings print on May 8 are the three items to watch in sequence.
See the live data behind this article on ORTEX.
Open IBRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
